{"id":"NCT00160706","sponsor":"UCB Pharma SA","briefTitle":"A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease","officialTitle":"A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2005-09-12","resultsPosted":"2013-07-04","lastUpdate":"2018-08-07"},"enrollment":310,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol (CDP870)","otherNames":["Cimzia","CDP870","CZP"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \\[NCT00152490\\] or CDP870-032 \\[NCT00152425\\] due to an exacerbation of Crohn's Disease.","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months)","timeFrame":"Up to 84 months from Study Entry (Week 0) to the Study End (Week 362 ) and the Safety Follow-up (Week 372)","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":94.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":141,"countries":["United States","Australia","Austria","Belarus","Belgium","Bulgaria","Canada","Czechia","Denmark","Estonia","Germany","Hungary","Israel","Italy","New Zealand","Norway","Poland","Russia","Serbia","Singapore","Slovenia","South Africa","Spain","Ukraine"]},"refs":{"pmids":["20363366"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":138,"n":310},"commonTop":["Crohn's disease","Abdominal pain","Arthralgia","Headache","Nasopharyngitis"]}}